Leplège A, Ecosse E, Archambau F, Arlot S, Bachelot I, Bercovici J-P, Bouchard P, Colle M, Dewailly D, Hassler P, Lorcy Y, Luton J-P, Roger P, Valensi P, Schaison G
EA 2494, UFR Cochin-Port Royal, Université Paris V, 27 rue du Faubourg Saint Jacques, F-75014 Paris.
Ann Endocrinol (Paris). 2003 Jun;64(3):191-7.
This study forms part of a research project seeking to develop a standardized questionnaire by which clinicians can assess the impact of growth hormone (GH) deficiency and its treatment on the "perceived health" or health-related quality of life of adults. The specific aim of this study was to translate and adapt for French patients the AGHDA (Adult Growth Hormone Deficiency Assessment) a standardized health-related quality of life measure for use with GH-deficient adults, initially developed in the United Kingdom, and to collect data which could be used to assess the main psychometric characteristics of its French version the ISPA-HC (Indicateur de Santé Perceptuelle Adulte-Hormone de Croissance). The main properties analyzed are: 1/ The scale's acceptability, as determined by means of face-to-face interviews with a small number of subjects, then by an ad hoc questionnaire administered during a test-retest study; 2/ The scale's reliability, as determined by a test-retest study (with a 15-days interval between tests); 3/ The scale's concurrent validity, as expressed by comparison with scores obtained by means of a generic quality of life scale, the ISPN (the French version of the Nottingham Health Profile). The results of this first trial with the ISPA-HC are conforming to what one can expect from a good instrument. The ISPA-HC has been shown to have very good levels of reliability and internal consistency. Its scores show a close correlation with those of the ISPN (the French version of the Nottingham Health Profile). This instrument can be used to measure variations in the perceived health of subjects with growth hormone deficiency. Its responsiveness to change is to be examined in subsequent studies.
本研究是一个研究项目的一部分，该项目旨在开发一份标准化问卷，通过它临床医生能够评估生长激素（GH）缺乏症及其治疗对成年人“感知健康”或与健康相关的生活质量的影响。本研究的具体目标是将AGHDA（成人生长激素缺乏症评估）翻译成法语并使其适用于法国患者，AGHDA是一种最初在英国开发的用于评估生长激素缺乏症成年人健康相关生活质量的标准化测量工具，并收集可用于评估其法语版本ISPA-HC（成人感知健康-生长激素指标）主要心理测量特征的数据。分析的主要特性包括：1/量表的可接受性，通过与少数受试者进行面对面访谈，然后在重测研究期间通过特设问卷来确定；2/量表的信度，通过重测研究（两次测试间隔15天）来确定；3/量表的同时效度，通过与使用通用生活质量量表ISPN（诺丁汉健康量表的法语版本）获得的分数进行比较来体现。首次使用ISPA-HC进行试验的结果符合对一个良好工具的预期。结果表明，ISPA-HC具有非常好的信度和内部一致性水平。其分数与ISPN（诺丁汉健康量表的法语版本）的分数密切相关。该工具可用于测量生长激素缺乏症患者感知健康的变化。其对变化的反应性将在后续研究中进行考察。
